阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的疗效观察
Effect of Azithromycin Combined with Xiao’er Xiaoji Zhike Oral Liquid on Mycoplasma Pneumonia in Children

目的：对于小儿支原体肺炎疾病，研究应用阿奇霉素联合小儿消积止咳口服液进行治疗的临床效果。方法：2023年1月~2023年12月期间，从来我医院进行小儿支原体肺炎治疗的患者中随机选择100例，其中50例应用阿奇霉素进行治疗，作为对照组；另外50例在阿奇霉素的基础上加用小儿消积止咳口服液，作为研究组。连续治疗2个疗程后对两组临床指标进行对比和评价。结果：研究组临床疗效为96.00%，对照组为76.00%，P < 0.05，研究组疗效更优。研究组患者的发热、咳嗽、肺部啰音以及X线片上的肺部病变消失得比对照组更快，P < 0.05。两组患儿在接受治疗后，比较IgM值、IgA值和血清CRP值，研究组各项指标显著降低，优于对照组，P < 0.05。从住院时间来看，研究组为(10.20 ± 2.85)天，低于对照组的(13.32 ± 3.10)天，P < 0.05。比较生活质量评分，结果发现在治疗前两组评分相差不多，不具备统计学意义，P > 0.05；而在治疗后，研究组改善十分明显，且显著优于对照组，P < 0.05。记录、统计两组不良反应发生情况，结果研究组不良反应发生率为10.00%，对照组为12.00%，虽有差异，但是差异不具备统计学意义，P > 0.05。结论：通过联用阿奇霉素联合使用阿奇霉素与小儿消积止咳口服液治疗小儿支原体肺炎，可以显著减少治疗时长，提高治疗效果，改善患者生活质量，优化免疫功能指标，降低不良反应发生率。
Objective: To study the clinical effect of azithromycin combined with Xiao’er Xiaoji Zhike oral liquid for treatment of mycoplasma pneumonia in children. Methods: From January 2023 to December 2023, 100 cases of pediatric mycoplasma pneumonia treated in our hospital were randomly se-lected, 50 of which were treated with azithromycin as the control group; in addition to azithromycin, the other 50 cases were treated with Xiao’er Xiaoji Zhike oral liquid as the study group. After 2 con-secutive courses of treatment, the clinical indexes of the two groups were compared and evaluated. Results: The clinical efficacy was 96.00% in the study group and 76.00% in the control group (P < 0.05). Fever, cough, lung rales and lung lesions on X-ray films disappeared faster in the study group than in the control group (P < 0.05). After treatment, the IgM value, IgA value and serum CRP value of the two groups were compared, and the indexes of the study group were significantly decreased, which was better than that of the control group (P < 0.05). The length of hospitalization in the study group was (10.20 ± 2.85) days, which was lower than that in the control group (13.32 ± 3.10) days, P < 0.05. The results showed that the scores of the two groups were similar before treatment, without statistical significance (P > 0.05); after treatment, the study group improved significantly and was significantly better than the control group (P < 0.05). The occurrence of adverse reactions in the two groups was recorded and analyzed. The incidence of adverse reactions was 10.00% in the study group and 12.00% in the control group. Although there was a difference, the difference was not sta-tistically significant (P > 0.05). Conclusion: The combination of azithromycin and Xiao’er Xiaoji Zhike oral liquid in the treatment of pediatric mycoplasma pneumonia can significantly reduce the dura-tion of treatment, improve the therapeutic effect, improve the